Clinical Trials Directory

Trials / Completed

CompletedNCT04524234

Cardiac Dysfunction in Critically Ill Patients With COVID-19

Status
Completed
Phase
Study type
Observational
Enrollment
132 (actual)
Sponsor
Sahlgrenska University Hospital · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers

Summary

Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients infected with COVID-19.

Detailed description

Cardiac dysfunction has been reported to be common in patients infected with COVID-19. The aim of this study is to evaluate the clinical importance of cardiac dysfunction in critically ill patients with COVID-19. Patients admitted to the intensive care unit, with COVID-19 are examined with echocardiography for assessment of left and right ventricular dysfunction within 72 hours from admission and repeated after four to seven days. Cardiac dysfunction was defined as having either left ventricular (LV) dysfunction, defined as having an ejection fraction \<50% and/or regional hypokinesia, or right ventricular (RV) dysfunction, defined as having a tricuspid annular plane excursion (TAPSE) \<17mm or a moderate/severe RV dysfunction assessed visually. The cardiac biomarkers troponin and NTproBNP and clinical data are recorded at time of each echo. Mortality status is recorded at 30 days.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEchocardiographyEchocardiography for assessment of cardiac function

Timeline

Start date
2020-04-20
Primary completion
2020-08-31
Completion
2020-09-30
First posted
2020-08-24
Last updated
2020-12-24

Locations

5 sites across 1 country: Sweden

Source: ClinicalTrials.gov record NCT04524234. Inclusion in this directory is not an endorsement.